Skip to main content
Bruce A. Chabner, The Oncologist
As The Oncologist marks a milestone year, its 25th anniversary, we reflect on our good fortune to have been witnesses and participants in the remarkable expansion of oncological practice over the past quarter century, as molecular oncology and immunotherapy have changed cancer care. Our hope is that The Oncologist has been a worthwhile effort, and we give special thanks to our authors, readers, and dedicated staff.
*In celebration of our 25th anniversary we are pleased to provide all readers free access to all content.
Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.
Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations.
Opioids form the cornerstone of pain management in cancer patients, but the crisis of opioid addiction has resulted in significant challenges facing patients, physicians, lawmakers, and communities across the nation. This series is focused to help clinicians manage the opioid crisis while ensuring adequate pain management for their patients.
Copyright © The Oncologist Community 2020. All rights reserved.